Lama-84
Référence 300261
Conditionnement : 1cryovial
Marque : CLS Cell Lines Service
Lama-84 Cells
General information
Description | LAMA-84 is a human cell line derived from the peripheral blood of a patient with chronic myeloid leukemia (CML) in blast crisis. This cell line is characterized by the presence of the Philadelphia chromosome, which results in the BCR-ABL fusion gene, a hallmark of CML. The BCR-ABL oncogene is known for its role in increasing tyrosine kinase activity, which promotes various signaling pathways leading to uncontrolled cell proliferation and resistance to apoptosis. LAMA-84 cells are thus an invaluable model for studying the molecular mechanisms of CML progression and for evaluating the efficacy of tyrosine kinase inhibitors (TKIs) in a pre-clinical setting. In research, LAMA-84 has been extensively used to understand the biology of CML, especially in the context of drug resistance and disease evolution. Studies involving this cell line have helped in elucidating the cellular responses to different generations of TKIs, such as imatinib, dasatinib, and nilotinib. Moreover, LAMA-84 has contributed to the investigation of new therapeutic strategies aimed at overcoming TKI resistance, including the testing of combination therapies that target other signaling pathways synergistically affected by the BCR-ABL fusion protein. |
---|---|
Organism | Human |
Tissue | Blood |
Disease | Chronic myeloid leukemia |
Synonyms | LAMA-84, LAMA84, Lama84 |
Characteristics
Age | 29 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Round cells |
Growth properties | Suspension, some adherent cells |
Identifiers / Biosafety / Citation
Citation | Lama-84 (Cytion catalog number 300261) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Surface antigens | GPIIb/IIIa+, GPIIIa+ |
---|---|
Viruses | EBNA, EA, and VCA were not detected |
Mutational profile | BCR-ABL1 pos |
Handling
Culture Medium | Ham's F12, w: 1.0 mM stable Glutamine, w: 1.0 mM Sodium pyruvate, w: 1.1 g/L NaHCO3 (Cytion article number 820600a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Doubling time | 30 hours |
Subculturing | Cells adhering to the bottom of the cell culture flask may be dislodged by shaking. Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 10^5 cells/ml and keep the cell concentration within the range of 1 x 10^5 to 1 x 10^6 cells/ml for optimal growth. |
Split ratio | A ratio of 1:2 to 1:3 is recommended |
Seeding density | 1 to 2 x 10^4 cells/cm^2 |
Freezing recovery | After thawing, plate the cells at 5 x 10^4 cells/cm^2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | CSF1PO: 11,12,13 D13S317: 11 D16S539: 11 D5S818: 11,12 D7S820: 11 TH01: 6,7 TPOX: 10 vWA: 14,17 D3S1358: 14,17 D21S11: 29,30,31 D18S51: 13 Penta E: 7 Penta D: 10 D8S1179: 10,15 FGA: 21,22 D1S1656: 15,15.3 D6S1043: 10,20 D2S1338: 17 D12S391: 18,24 D19S433: 13 |
HLA alleles | A*: 02:01:01, 25:01:01 B*: 18:01:01, 44:02:01 C*: 05:01:01, 12:03:01 DRB1*: 04:02:01, 15:01:01G DQA1*: 01:02:01, 03:01:01 DQB1*: 03:02:01, 06:02:01 DPB1*: 09:01:01, 23:01:01 E: 01:01:01 |